Semaglutide vs Prostamax
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
SemaglutideAnti-Aging & Longevity
Prostamax- Summary
- Semaglutide is an FDA-approved GLP-1 receptor agonist originally developed for type 2 diabetes that has proven remarkably effective for weight loss. Clinical trials show average 15–20% body weight reduction. It is marketed as Ozempic (diabetes) and Wegovy (weight management).
- Prostamax is a tetrapeptide bioregulator (Lys-Glu-Asp-Pro) developed by Professor Vladimir Khavinson, tissue-specific for the prostate gland. It supports prostate epithelial cell function, promotes normalization of prostate tissue, and is studied for its potential in benign prostatic hyperplasia (BPH), prostatitis, and prostate anti-aging. It is one of the more widely used Khavinson bioregulators among men over 40.
- Half-Life
- ~7 days
- Short (minutes); sustained gene-regulatory effects
- Admin Route
- SubQ, Oral
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg
- 10 mg per day
- Frequency
- Once weekly, subcutaneous
- Daily for 10–30 days
- Key Benefits
- Average 15–20% body weight reduction in clinical trials (STEP trials)
- Significant reduction in appetite and food cravings
- Improvement in blood sugar control and insulin sensitivity
- Reduces cardiovascular risk (SELECT trial: 20% reduction in MACE)
- May reduce risk of kidney disease
- Improves metabolic markers (cholesterol, blood pressure)
- FDA-approved — extensively studied with robust safety data
- Weekly dosing convenience
- Supports normalization of prostate tissue architecture
- May reduce prostate enlargement associated with BPH
- Anti-inflammatory effects on prostatic tissue
- Reduces prostate cell apoptosis from oxidative stress
- Potential support in chronic prostatitis
- Anti-aging effects on prostate glandular tissue
- Complementary to conventional BPH therapies
- Side Effects
- Nausea (most common, especially during titration)
- Vomiting
- Diarrhea or constipation
- Abdominal discomfort
- +4 more
- Generally well tolerated in available research
- Mild injection site reactions
- No significant adverse urological events reported at standard doses
- Stacks With
- —
- —